CA3208560A1 - Methods for treating pulmonary hypertension in patients with left ventricular assist device implantation - Google Patents

Methods for treating pulmonary hypertension in patients with left ventricular assist device implantation Download PDF

Info

Publication number
CA3208560A1
CA3208560A1 CA3208560A CA3208560A CA3208560A1 CA 3208560 A1 CA3208560 A1 CA 3208560A1 CA 3208560 A CA3208560 A CA 3208560A CA 3208560 A CA3208560 A CA 3208560A CA 3208560 A1 CA3208560 A1 CA 3208560A1
Authority
CA
Canada
Prior art keywords
macitentan
per day
aprocitentan
patient
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3208560A
Other languages
English (en)
French (fr)
Inventor
Mark Rocco
Mona SELEJ
Carol ZHAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CA3208560A1 publication Critical patent/CA3208560A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M60/00—Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance
    • A61M60/90—Details not provided for in groups A61M60/40, A61M60/50 or A61M60/80
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Mechanical Engineering (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3208560A 2021-02-26 2022-02-25 Methods for treating pulmonary hypertension in patients with left ventricular assist device implantation Pending CA3208560A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163154348P 2021-02-26 2021-02-26
US63/154,348 2021-02-26
PCT/EP2022/054742 WO2022180194A1 (en) 2021-02-26 2022-02-25 Methods for treating pulmonary hypertension in patients with left ventricular assist device implantation

Publications (1)

Publication Number Publication Date
CA3208560A1 true CA3208560A1 (en) 2022-09-01

Family

ID=80933151

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3208560A Pending CA3208560A1 (en) 2021-02-26 2022-02-25 Methods for treating pulmonary hypertension in patients with left ventricular assist device implantation

Country Status (6)

Country Link
US (1) US20240299384A1 (https=)
EP (1) EP4297754A1 (https=)
JP (1) JP2024507905A (https=)
CN (1) CN116887835A (https=)
CA (1) CA3208560A1 (https=)
WO (1) WO2022180194A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105693624B (zh) * 2013-06-14 2018-05-18 杭州普晒医药科技有限公司 马西替坦晶体及其制备方法、其药物组合物和用途
PT3897646T (pt) * 2018-12-21 2024-07-08 Actelion Pharmaceuticals Ltd Macitentano para tratamento de hipertensão arterial pulmonar

Also Published As

Publication number Publication date
CN116887835A (zh) 2023-10-13
WO2022180194A1 (en) 2022-09-01
JP2024507905A (ja) 2024-02-21
US20240299384A1 (en) 2024-09-12
EP4297754A1 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
TW201634048A (zh) 治療法布裡病之給藥方案
KR20260004440A (ko) 종양 괴사 인자 알파의 소분자 저해제를 사용한 건선 치료
US20120004188A1 (en) Use of ranolazine for treating pulmonary hypertension
KR20210038708A (ko) 유데나필 조성물을 이용하여 폰탄 환자에서 심근 성능을 개선시키는 방법
US20220257595A1 (en) Macitentan for use in treating portopulmonary hypertension
TW200808313A (en) Compositions and methods for treating rheumatoid arthritis
TW201540300A (zh) 慢性腎臟病之進展抑制或改善用製劑
US12485119B2 (en) Methods of treating pulmonary arterial hypertension
US20240299384A1 (en) Methods for treating pulmonary hypertension in patients with left ventricular assist device implantation
US20230000865A1 (en) Pharmaceutical composition for the treatment of pulmonary vascular disease and/or cardiac dysfunction in fontan-palliated patients
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
TW201904584A (zh) 減少或預防第ｉｉ型糖尿病患者中心血管事件之方法
US20240307397A1 (en) Pharmaceutical composition comprising pi3k and dna-pk dual inhibitor for preventing or treating peripheral t cell lymphoma
WO2024099953A1 (en) Combination of macitentan and tadalafil for the treatment of pulmonary arterial hypertension
TWI846676B (zh) 用於治療胰腺癌的治療組合物
JP5992086B1 (ja) 月経前不快気分障害及び／又は月経前症候群の予防、改善及び治療用医薬組成物
WO2022235779A1 (en) Methods of administering terevalefim
HK40003387A (en) Therapeutic compositions for treating pancreatic cancer
Chentir et al. CLINICAL AND ECHOCARDIOGRAPHIC FINDINGS IN ST ELEVATION MYOCARDIAL INFARCTION (STEMI) ACCORDING TO GENDER: PP. 13.368

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260408